This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.

Paramyotonia congenitaParamyotonia Congenita

📋 Contents and key points
ItemDetails
A. Classification codesICD-10: G71.1 | Special Copayment Reduction: V012 | Registration validity period: 5 years
B. SynonymsParamyotonia Congenita (PMC), Eulenburg disease, SCN4A-related paramyotonia
C. Adult onsetLow likelihood of first onset in adulthood — onset is from birth or in infancy to childhood, but because symptoms are mild, some cases are first diagnosed in adulthood.
1. HistoryGo to section
2. CausesGo to section
3. GeneticsGo to section
4. General epidemiologyGo to section
5. PathophysiologyGo to section
6. SymptomsGo to section
7. SignsGo to section
8. ScreeningGo to section
9. DiagnosisGo to section
10. TreatmentGo to section
11. PrognosisGo to section
12. PreventionGo to section
13. ReferencesGo to section

1. History

Paramyotonia Congenita (PMC) was first described in 1886 by the German neurologist Albert von Eulenburg and is also called 'Eulenburg disease' after him. Eulenburg observed a family in which muscle stiffness and paralysis triggered by exercise and exposure to cold appeared across several generations, and documented it systematically. The term 'paramyotonia' was adopted to emphasize the paradoxical feature that, although similar to myotonia congenita (Thomsen disease), it worsens with exercise (no warm-up). Until the mid-20th century, classification was based on clinical phenotype, but in 1991 Ptácek et al. first identified gain-of-function variants in the SCN4A gene (the gene encoding the sodium ion channel Nav1.4) as the cause of PMC. Subsequently, as phenotypic spectrum continuity was revealed between SCN4A variants and hyperkalemic periodic paralysis (HypoPP type 2) and various sodium channel-related phenotypes, an integrated understanding of SCN4A-related ion channelopathies developed. Today, PMC is classified as the representative phenotype among SCN4A-related sodium channelopathies characterized by cold-induced myotonia and paralysis.

2. Causes

Paramyotonia congenita is an autosomal dominant disorder caused by gain-of-function pathogenic variants in the SCN4A gene (17q23.3). SCN4A encodes the alpha subunit of the skeletal muscle voltage-gated sodium channel (Nav1.4), which is essential for the initiation and propagation of muscle action potentials.

3. Genetics

PMC follows an autosomal dominant inheritance pattern and is transmitted from an affected parent to a child with a 50% probability. De novo mutations also occur rarely. Penetrance is generally high, but expressivity varies by variant. Diagnosis is confirmed by sequencing of the entire SCN4A gene or a gene panel. A genotype-phenotype correlation exists to some degree, but variation in symptom severity is observed even within families carrying the same variant.

Phenotypes associated with SCN4A variantsFeatures
Paramyotonia congenita (PMC)Cold- and exercise-induced myotonia → progresses to paralysis, no warm-up
Hyperkalemic periodic paralysis (HyperPP)Episodic paralysis, elevated serum potassium, may be accompanied by myotonia
Sodium channel myotonia (SCM)Predominantly myotonia, no paralysis
Hypokalemic periodic paralysis type 2 (HypoPP2)Episodic paralysis, decreased serum potassium

4. General epidemiology

Paramyotonia congenita is a very rare disease, and its exact prevalence is difficult to estimate. Worldwide prevalence is estimated at about 1/200,000–1/500,000, but the actual prevalence may be higher due to underdiagnosis. Prevalence is equal between sexes, and it is known to occur in all ethnic groups. In some European countries, specific founder mutations are observed at relatively high frequency within populations. Diagnosis is commonly delayed in patients with mild clinical symptoms, so the actual number of patients is likely greater than reported. Age of onset varies from birth to childhood, and symptom onset may be related to region and season, reflecting sensitivity to cold.

5. Pathophysiology

The Nav1.4 channel is responsible for the depolarization phase of the skeletal muscle action potential, and normally fast inactivation occurs within a few milliseconds after the action potential, restoring the membrane potential to its resting state. SCN4A gain-of-function variants associated with PMC impair or delay this inactivation process, causing the channel to remain in the open state abnormally long or to repeatedly reactivate.

As a result, a persistent inward sodium current occurs, placing the muscle cell membrane in a state of excessive depolarization. Initially, myotonia appears due to repetitive action potentials; if excessive depolarization persists, most sodium channels become locked in the inactivated state and depolarization block occurs, in which action potentials can no longer be generated, and this manifests as clinical paralysis.

Symptom worsening with cold occurs because inactivation of the Nav1.4 channel is further delayed at low temperatures, increasing the persistent sodium current. This explains why PMC, unlike myotonia congenita (ClC-1 variants), lacks the warm-up phenomenon and instead worsens with continued exercise.

6. Symptoms

Key clinical features

Affected areas

Accompanying periodic paralysis

7. Signs

Clinical examination

EMG findings

Laboratory findings

8. Screening

9. Diagnosis

The diagnosis is suspected based on clinical features (cold- and exercise-induced paradoxical myotonia, progression to paralysis) and EMG findings, and confirmed by molecular genetic testing of the SCN4A gene.

Molecular genetic testing

Ancillary diagnosis

Differential diagnosis

10. Treatment

Patients with mild symptoms can be managed by avoiding cold and excessive exercise alone. If symptoms impair daily functioning, drug treatment is considered.

Drug therapy

Non-pharmacological treatment

Anesthetic management

11. Prognosis

Paramyotonia congenita rarely causes life-threatening complications and has a nonprogressive course. Most patients have a normal life expectancy. Symptoms can be effectively controlled by avoiding cold and with drug treatment. In some patients, the frequency or severity of paralytic attacks may change with increasing age, and some may develop persistent mild muscle weakness. When periodic paralysis is present, there are reports that repeated paralytic attacks can lead to permanent muscle weakness in the long term, so early treatment and management of triggers are important. Symptoms may change during pregnancy, and the effect on the newborn is minimal.

12. Prevention

13. References

  1. Ptácek LJ, George AL Jr, Griggs RC, et al. Identification of a mutation in the gene causing hyperkalemic periodic paralysis. Cell. 1991;67(5):1021–1027. PMID: 1659948
  2. Lerche H, Heine R, Pika U, et al. Human sodium channel myotonia: slowed channel inactivation due to substitutions for a glycine within the III-IV linker. J Physiol. 1993;470:13–22. PMID: 8308735
  3. Statland JM, Fontaine B, Hanna MG, et al. Review of the diagnosis and treatment of periodic paralysis. Muscle Nerve. 2018;57(4):522–530. PMID: 28846808
  4. Heine R, Pika U, Lehmann-Horn F. A novel SCN4A mutation causing myotonia aggravated by cold and potassium. Hum Mol Genet. 1993;2(9):1349–1353. PMID: 8242056
  5. Suetterlin KJ, Männikkö R, Hanna MG. Mutation-specific effects of mexiletine on sodium channel function in a mouse model of myotonia. Exp Neurol. 2015;270:28–37. PMID: 25930180
  6. Vicart S, Sternberg D, Fontaine B, Meola G. Human skeletal muscle sodium channelopathies. Neurol Sci. 2005;26(4):194–202. PMID: 16193245
  7. Weber MA, Nielles-Vallespin S, Huttner HB, et al. Evaluation of patients with paramyotonia at 31P MRS. Neurology. 2006;66(10):1621–1627. PMID: 16769952
  8. Kim JB. Channelopathies. Korean J Pediatr. 2014;57(1):1–18. PMID: 24578715
  9. Stunnenberg BC, Raaphorst J, Groenewoud HM, et al. Effect of mexiletine on muscle stiffness in patients with nondystrophic myotonia evaluated using aggregated N-of-1 trials. JAMA. 2018;320(22):2344–2353. PMID: 30535218
  10. Riggs JE, Griggs RC. Diagnosis and treatment of the periodic and myotonic paralysis syndromes. Neurol Clin. 1983;1(1):51–64. PMID: 6634580